DOCSLIB.ORG

RAS-Targeted Therapies Amanda R

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RAS-Targeted Therapies Amanda R RAS-targeted therapies Amanda R. Moore, Scott C. Rosenberg, Frank McCormick & Shiva Malek The RAS (KRAS, NRAS and HRAS) family is the most are being investigated. Such strategies include inhibition frequently mutated gene family in cancers, and, of SOS1 and SHP2, which promote RAS activation, and consequently, investigators have sought an effective RAS inhibition of pathways downstream of RAS. Many of these inhibitor for more than three decades. Now, allele-specific potential therapies are being tried in combinations with covalent inhibitors against the most frequently mutated RAS inhibitors. Mutation-specific biochemical properties, version of RAS in NSCLC, KRAS-G12C, are in late-stage the spectrum of co-mutations, and the tissue of origin are clinical trials, and other strategies to inhibit this pathway likely to affect the effectiveness of such treatments. RAS mutational spectrum Select single-agent inhibitors in clinical development for RAS-mutant tumours Drug Biomarker Disease setting Study Clinical trial Head and neck Clinical development of potential therapies for RAS-mutant tumours phase number 5% 35% squamous cell 45% KRAS- G12C inhibitors carcinoma Activation of receptor tyrosine kinases, such as members of KRAS-G12C. GTP-bound RAS activates downstream signalling Sotorasib (AMG 510) KRASG12C mutation NSCLC III NCT04303780 91% G12 17% Lung the EGFR family, leads to a cascade of events at the membrane by binding to the RAS-binding domain of effector proteins, Adagrasib (MRTX849) KRASG12C mutation NSCLC III NCT04685135 32% adenocarcinoma G12A inner leaflet culminating in the activation of RAS. Inhibition at such as RAF and p110, to activate the MAPK and PI3K signalling JNJ-74699157 (ARS-3248) KRASG12C mutation Advanced solid tumours I NCT04006301 Melanoma 29% G12C PDAC various levels — such as EGFR, SOS or SHP2 — decreases the cascades, respectively. Both the MAPK and PI3K signalling GDC-6036 KRASG12C mutation Advanced solid tumours I NCT04449874 Bladder G12D rate at which inactive KRAS–GDP becomes active KRAS–GTP cascades can be inhibited at each kinase tier. Data compiled D-1553 KRASG12C mutation NSCLC, CRC I NCT04585035 urothelial 4% 30% G12F a carcinoma 86% and reduces the GTP-bound RAS population. Mutant RAS from ClinicalTrials.gov and AccessData.FDA.gov. Only effective JDQ433 KRASG12C mutation Advanced solid tumours I/II NCT04699188 G12L b Colorectal 41% proteins accumulate in the GTP-bound state. A number against monomeric BRAF (BRAF-V600E/K). Approved for SOS inhibitors 45% G12R c adenocarcinoma of approaches have been developed to directly inhibit RAS, the treatment of BRAF-mutant melanoma. Approved for the BI-1701963 KRAS mutations Advanced or metastatic solid tumours I NCT04111458 68% G12 G12S including covalent allele-specific inhibitors that bind to treatment of paediatric patients with NF1 mutations. G12V SHP2 inhibitors The most frequently mutated RAS G12Y RMC-4630 Mutations that hyperactivate the MAPK pathway Relapsed or refractory solid tumours I NCT03634982 isoform, codon and amino acid 23% EGFR TNO155 EGFR or KRASG12C mutations Advanced solid tumours I NCT03114319 substitution vary by tissue type family BBP-398 Mutations that hyperactivate the MAPK pathway Advanced solid tumours I NCT04528836 and cancer. Whereas NRAS is the 46% Farnesyltransferase inhibitors 17% most frequently mutated isoform Tipifarnib HRAS mutations HNSCC, NSCLC II NCT02383927, in melanoma, KRAS mutations 85% G12 NCT03496766 dominate in lung, pancreatic and KRAS Q61R Q61H Inhibitors of RAS processing RAF inhibitors colorectal cancers. Even within NRAS Tipifarnib EGFR inhibitors Belvarafenib NRAS mutations Advanced melanoma I NCT04835805 KRAS-mutated cancers, the most HRAS Q61K Cysmethynil Cetuximab LXH254 MAPK pathway mutation Advanced solid tumours I NCT02607813 UCM-1336 Panitumumab frequently mutated codon and the 46% 30% MEK inhibitors distributions of amino acid substitutions at those mutated codons Deltarasin Erlotinib NHTD Gefitinib Binimetinib (MEK162) NRAS mutation Unresectable or metastatic melanoma III NCT01763164 (12 or 61) are different for each tissue type, as shown in pie charts 13% GDP ERK inhibitors beside the relevant organ. Data from TCGA and AACR Project GENIE. 85% Q61 Q61L Allele-specific RAS inhibitors Pan-EGFR family LY3214996 BRAF or NRAS mutations Metastatic melanoma and NSCLC I NCT02857270 Sotorasib (AMG 510) inhibitors Adoptive cell therapies RAS GEF Adagrasib (MRTX849) Afatinib Anti- RAS- G12D mTCR HLA-A*11:01 RASG12D mutation Advanced solid tumours I/II NCT03745326 O JNJ-74699157 (ARS-3248) GDP Neratinib Direct RAS inhibitor structures Anti- RAS- G12V mTCR HLA-A*11:01 RASG12V mutation Advanced solid tumours I/II NCT03190941 O O GDC-6036 GAP GRB2 G12V F N D-1553 BI-1701963 Anti-RAS-G12V TCR HLA-A*11:01 RAS mutation Advanced solid tumours I/II NCT04146298 P GTP O N N i SOS BAY-293 siRNA strategies H NC JDQ433 N ARS-1620 BI-3406 KRAS-G12D iExosomes KRASG12D mutation PDAC I NCT03608631 N N N N ARS-853 SHP2 JAB-3068 Cancer vaccines N F RM-007 Cl OH Cl F N RMC-4630 mRNA-5671 HLA-A*11:01 and/or HLA-C*08:02; KRASG12C, NSCLC, non- MSI- H CRC, PDAC I NCT03948763 N OH N N RM-008 RAS TNO155 KRASG12D, KRASG12V or KRASG13D mutations N N N O RLY-1971 N N O KRAS antisense oligonucleotides O GTP Autophagy BBP-398 Select combination therapies in clinical development for RAS-mutant cancers F Cl N OH KRAS-G12D iExosomes F SHP099 Drugs Biomarker Disease setting Study Clinical trial N siG12D LODER phase number AZD4785 RMC-4550 ARS-853 ARS-1620 Adagrasib (MRTX849) Sotorasib (AMG 510) KRAS- G12C combinations MAPK PI3K Hydroxychloroquine Sotorasib and antibodies to PD1 or PDL1 KRASG12C mutation Advanced NSCLC II NCT03600883 Belvarafenib pathway pathway LXH254 Adagrasib and TNO155 KRASG12C mutation Advanced or metastatic solid tumours I/II NCT04330664 Regions of RAS that could or are being targeted by therapeutics Lifirafenib (BGB-283) GDC-0077 JDQ433 and TNO155 KRASG12C mutation Advanced solid tumours I/II NCT04699188 PLX8394 Taselisib (GDC-0032) GDC-6036 and atezolizumab, cetuximab, KRASG12C mutation Advanced or metastatic solid tumours I NCT04449874 Sorafenib bevacizumab or erlotinib Regions targeted by clinical compounds a RAF p110 Alpelisib Vemurafenib Copanlisib SOS inhibitor combinations Switch-II pocket Switch-II groove BI-2852 Dabrafeniba Duvelisib BI-1701963 and trametinib KRAS mutation Advanced or metastatic solid tumours I NCT04111458 Sotorasib Switch I/II pocket Encorafeniba Switch-II 2C07 Idelalisib (AMG 510) LY3009120 P P BI-1701963 and irinotecan KRAS mutation Metastatic CRC I NCT04627142 AZ-628 SHP2 inhibitor combinations MEK AKT Ipatasertib Switch-I TAK-632 TNO155 and spartalizumab EGFR or ALK WT NSCLC Advanced solid tumours Ib NCT04000529 GppNHp Pimasertib TNO155 and ribociclib EGFR or ALK WT NCSLC, KRAS- mutant CRC or NSCLC Advanced solid tumours Ib NCT04000529 RAF inhibitor combinations 90° PD-0325901 P Binimetinib (MEK162)b Everolimus Belvarafenib and cobimetinib RAS or RAF mutations Locally advanced or metastatic tumours Ib NCT03284502 ERK mTOR Temsirolimus HRAS bound to GppNHp, Switch-II pocket (purple) of KRAS- Switch-II groove (purple) bound Switch I/II pocket of KRAS- Cobimetinibb LXH254 and an antibody to PD1 NRAS (melanoma) or KRAS (NSCLC) mutations Advanced solid tumours I NCT02607813 a non-hydrolysable G12C bound to sotorasib (AMG 510), to 2C07, the first covalent G12D (teal) bound to BI-2852, c Selumetinib LXH254 and trametinib, LTT462 or ribociclib KRAS or BRAF (NSCLC) or NRAS (melanoma) mutations Advanced or metastatic solid tumours Ib NCT02974725 nucleotide, as a reference a covalent RAS inhibitor (PDB: 6OIM; RAS inhibitor (PDB: 5VBZ; which disrupts the RAS–SOS1 Trametinibb for orientation (PDB: 5P21). compound identifier: MOV). compound identifier: 92V). interaction (PDB: 6GJ8). BGB-283 and PD-0325901 KRAS- mutant NSCLC or endometrial cancer Advanced or refractory solid tumours Ib NCT03905148 LY3214996 MEK inhibitor combinations Ulixertinib (BVD-523) Other potentially targetable regions Cobimetinib and atezolizumab KRAS mutation Advanced and metastatic NSCLC II NCT03600701 GDC-0994 Cobimetinib and RMC-4630 Mutations that hyperactivate the MAPK pathway Relapsed or refractory solid tumours Ib/II NCT03989115 SOS interface KO-947 Clinical compound Selumetinib and MK-8353 RAS or RAF mutations Advanced solid tumours Ib NCT03745989 Dimer SCH-772984 SOS binding Proposed HRAS interface RAF–RAS–RBD FDA approved for other indications Trametinib and ponatinib KRAS mutation Advanced NSCLC I NCT03704688 Vtx-11e (including tumours without RAS mutations) interface (red) dimerization binding interface ERK inhibitor combinations MK-8253 Completed clinical trial of HRAS (PDB: interface (green) NS1 (yellow) of HRAS LY3214996 and midazolam, abemaciclib, or BRAF or RAS mutations Advanced or metastatic solid tumours I NCT02857270 1BKD). bound by NS1 (PDB: 4G0N). Terminated clinical trial nab-paclitaxel + gemcitabine monobody (gold) Cancer vaccine combinations (PDB: 5E95). mRNA-5671 and pembrolizumab HLA-A*11:01 and/or HLA-C*08:02 KRASG12C, KRASG12D, NSCLC, non-MSI- H CRC, PDAC I NCT03948763 135° 90° RBD interface KRASG12V or KRASG13D mutations Abbreviations References Affiliations Competing interests statement Reaction Biology Reaction Biology’s KRAS Drug Discovery Platform offers: CRC, colorectal cancer; DCAI, 4,6-dichloro-2- 1. Canon, J. et al. The clinical KRAS(G12C) inhibitor 5. Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. • Amanda R. Moore, Scott C. F.McC. is a consultant for the following companies:
Load more

Recommended publications
  • Analyst WCLC Presentation
    SOTORASIB AT THE 2020 WORLD CONFERENCE ON LUNG CANCER JANUARY 29, 2021 SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including BeiGene, Ltd. or any collaboration or potential collaboration in pursuit of therapeutic antibodies against COVID-19 (including statements regarding such collaboration’s, or our own, ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 or antibodies against targets other than the SARS-CoV-2 receptor binding domain, and/or to produce any such antibodies to potentially prevent or treat COVID-19), or the Otezla® (apremilast) acquisition (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K.
    [Show full text]
  • Elicio Therapeutics, Inc. Form S-1/A Filed 2021-07-13
    SECURITIES AND EXCHANGE COMMISSION FORM S-1/A General form of registration statement for all companies including face-amount certificate companies [amend] Filing Date: 2021-07-13 SEC Accession No. 0001193125-21-213558 (HTML Version on secdatabase.com) FILER Elicio Therapeutics, Inc. Mailing Address Business Address ONE KENDALL SQUARE ONE KENDALL SQUARE CIK:1555192| IRS No.: 452966790 | State of Incorp.:DE | Fiscal Year End: 1231 BUILDING 1400 WEST, BUILDING 1400 WEST, Type: S-1/A | Act: 33 | File No.: 333-257480 | Film No.: 211086788 SUITE 14303 SUITE 14303 SIC: 2834 Pharmaceutical preparations CAMBRIDGE MA 02139 CAMBRIDGE MA 02139 857-209-0056 Copyright © 2021 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents As filed with the Securities and Exchange Commission on July 13, 2021 Registration No. 333-257480 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ELICIO THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 45-2966790 (State or Other Jurisdiction of (Primary Standard Industrial (I.R.S. Employer Incorporation or Organization) Classification Code Number) Identification Number) One Kendall Square Building 1400 West, Suite 14303 Cambridge, MA 02139 (857) 209-0050 (Address, including zip code, and telephone number, including area code, of Registrants principal executive offices) Robert Connelly Chief Executive Officer Elicio Therapeutics, Inc. One Kendall Square Building 1400 West, Suite 14303 Cambridge, MA 02139 (857) 209-0050 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: John J.
    [Show full text]
  • Recent Advances in Oligonucleotide Therapeutics in Oncology
    International Journal of Molecular Sciences Review Recent Advances in Oligonucleotide Therapeutics in Oncology Haoyu Xiong 1, Rakesh N. Veedu 2,3 and Sarah D. Diermeier 1,* 1 Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand; [email protected] 2 Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia; [email protected] 3 Perron Institute for Neurological and Translational Science, Perth 6009, Australia * Correspondence: [email protected] Abstract: Cancer is one of the leading causes of death worldwide. Conventional therapies, including surgery, radiation, and chemotherapy have achieved increased survival rates for many types of cancer over the past decades. However, cancer recurrence and/or metastasis to distant organs remain major challenges, resulting in a large, unmet clinical need. Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. While no approved oligonucleotide drug currently exists for any type of cancer, results obtained in preclinical studies and clinical trials are encouraging. Here, we provide an overview of recent developments in the field of oligonucleotide therapeutics in oncology, review current clinical trials, and discuss associated challenges. Keywords: antisense oligonucleotides; siRNA; aptamers; DNAzymes; cancers Citation: Xiong, H.; Veedu, R.N.; 1. Introduction Diermeier, S.D. Recent Advances in Oligonucleotide Therapeutics in According to the Global Cancer Statistics 2018, there were more than 18 million new Oncology. Int. J. Mol. Sci. 2021, 22, cancer cases and 9.6 million deaths caused by cancer in 2018 [1].
    [Show full text]
  • Precision Medicine in Colorectal Cancer 2021
    Precision Medicine in Colorectal Cancer 2021 Michael Morse, MD Professor of Medicine Duke University Disclosures Biomarker Subgroups in CRC This lecture will not address MSI‐H and TMB‐H RAS mutation ± 45% PIK3CA/PTEN mutation 8% PIK3CA/PTEN mutation 1% p6 235-237, 2% 2% 1%2% 26% 2%2% Kinase inhibitor 8% MET inhibitor Anti‐HER2 Tx Wild type Anti‐PD‐1/PD‐L1 Anti‐EGFR therapies BRAF V600E BRAF inhibitor + anti‐EGFR ± MEK inhibitor Dienstmann. ASCO Ed Book. 2018. Slide credit: clinicaloptions.com Next‐generation sequencing results of TRIBE2 study BRAF V600E KRAS G12C HER2 Ampl HER2 Mut MSI‐H POLE mut TMB high Right sided 20% had “actionable” alterations Antoniotti C, Eur J Cancer. 2021 Aug 5;155:73‐84. BRAF V600E Targeting This section is courtesy John Strickler, MD BRAF V600E mutant mCRC has poor prognosis with chemotherapy Presented By Michael Lee at ASCO 2020 BRAFV600E mutations in metastatic CRC • ~5‐8% of CRC • Right sided • High grade • More likely to be MSI‐H • Poor prognosis • Limited benefit from anti‐EGFR therapy Strickler et al., Cancer Treat Rev. 2017 Nov;60:109‐119. Rationale for inhibition of BRAF + EGFR +/‐ MEK Presented By Eric Von Cutsem at 2018 ESMO GI Meeting BEACON CRC Phase 3 Study Design Kopetz et al., J Clin Oncol 38: 2020 (suppl; abstr 4039) Van Cutsem. JCO. 2019;[Epub]. Taberno. ESMO 2019. LBA32. Kopetz. NEJM. 2019;[Epub]. NCT02928224 BEACON: Updated Overall Survival Kopetz et al., J Clin Oncol 38: 2020 (suppl; abstr 4039) BEACON: Updated Objective Response Rates Kopetz et al., J Clin Oncol 38: 2020 (suppl; abstr 4039)
    [Show full text]
  • (FDA) Approved Bristol Myers Squibb's (Bms.Com) Br
    tools Approved Drugs (cemiplimab-rwlc) for patients with • On Dec. 18, 2020, the FDA approved locally advanced basal cell carcinoma Tagrisso® (osimertinib) (AstraZeneca, • On Feb. 5, 2021, the U.S. Food and Drug previously treated with a hedgehog astrazeneca.com) for adjuvant therapy Administration (FDA) approved Bristol pathway inhibitor (HHI) or for whom an after tumor resection in patients with ® Myers Squibb’s (bms.com) Breyanzi HHI is not appropriate and accelerated non-small cell lung cancer (NSCLC) whose (lisocabtagene maraleucel), a CD19- approval to Libtayo for patients with tumors have epidermal growth factor directed chimeric antigen receptor T-cell metastatic basal cell carcinoma previ- receptor exon 19 deletions or exon 21 therapy for the treatment of adult ously treated with an HHI or for whom an L858R mutations, as detected by an patients with relapsed or refractory large HHI is not appropriate. FDA-approved test. B-cell lymphoma after two or more lines • On Dec. 16, 2020, the FDA approved On Feb. 3, 2021, the FDA granted of systemic therapy, including diffuse ™ • Margenza (margetuximab-cmkb) ® large B-cell lymphoma not otherwise accelerated approval to Tepmetko (MacroGenics, macrogenics.com) in specified (including diffuse large B-cell (tepotinib) (EMD Serono, combination with chemotherapy for the lymphoma arising from indolent emdserono.com/us-en) for adult patients treatment of adult patients with with metastatic NSCLC harboring lymphoma), high-grade B-cell lymphoma, metastatic HER2-positive breast cancer primary mediastinal large B-cell mesenchymal-epithelial transition exon who have received two or more prior 14 skipping alterations. lymphoma, and follicular lymphoma anti-HER2 regimens, at least one of which grade 3B.
    [Show full text]
  • Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
    cancers Review Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies Alberto D’Angelo 1,* , Navid Sobhani 2 , Robert Chapman 3 , Stefan Bagby 1, Carlotta Bortoletti 4, Mirko Traversini 5, Katia Ferrari 6, Luca Voltolini 7, Jacob Darlow 1 and Giandomenico Roviello 8 1 Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK; [email protected] (S.B.); [email protected] (J.D.) 2 Section of Epidemiology and Population Science, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA; [email protected] 3 University College London Hospitals NHS Foundation Trust, 235 Euston Rd, London NW1 2BU, UK; [email protected] 4 Department of Dermatology, University of Padova, via Vincenzo Gallucci 4, 35121 Padova, Italy; [email protected] 5 Unità Operativa Anatomia Patologica, Ospedale Maggiore Carlo Alberto Pizzardi, AUSL Bologna, Largo Bartolo Nigrisoli 2, 40100 Bologna, Italy; [email protected] 6 Respiratory Medicine, Careggi University Hospital, 50139 Florence, Italy; [email protected] 7 Thoracic Surgery Unit, Careggi University Hospital, Largo Brambilla, 1, 50134 Florence, Italy; luca.voltolini@unifi.it 8 Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini, 6, 50139 Florence, Italy; [email protected] * Correspondence: [email protected] Received: 22 September 2020; Accepted: 5 November 2020; Published: 6 November 2020 Simple Summary: Genetic rearrangements of the ROS1 gene account for up to 2% of NSCLC patients who sometimes develop brain metastasis, resulting in poor prognosis. This review discusses the tyrosine kinase inhibitor crizotinib plus updates and preliminary results with the newer generation of tyrosine kinase inhibitors, which have been specifically conceived to overcome crizotinib resistance, including brigatinib, cabozantinib, ceritinib, entrectinib, lorlatinib and repotrectinib.
    [Show full text]
  • 5.01.540 Miscellaneous Oncology Drugs
    PHARMACY / MEDICAL POLICY – 5.01.540 Miscellaneous Oncology Drugs Effective Date: Aug. 1, 2021* RELATED MEDICAL POLICIES: Last Revised: July 13, 2021 5.01.543 General Medical Necessity Criteria for Companion Diagnostics Related to Replaces: N/A Drug Approval *This policy has been updated. View changes. Select a hyperlink below to be directed to that section. POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction Chemotherapy, often called chemo, is cancer treatment that uses drugs. Radiation and surgery treat one area of cancer. But chemo usually travels through the bloodstream to treat the whole body. Treating the whole body is called a systemic treatment. The goal of chemo is to either treat cancer or ease its symptoms. Treating cancer can be to cure it, decrease the chance it will return, or stop or slow its growth. Easing cancer symptoms without trying to cure the cancer is called palliative therapy. Chemotherapy drugs can be used in many different ways. Chemo can make a tumor smaller before surgery or radiation, destroy cancer cells that surgery or radiation didn’t treat, help other treatments work better, or kill cancer cells that have come back or spread. Chemotherapy is given in different ways. This includes by mouth (oral), through a vein (intravenous), by a shot (injection), or with a cream rubbed onto the skin (topical). In some cases, chemo is injected between the layers of tissue covering the brain and spinal cord (intrathecal), is given into the belly area (intraperitoneal), or is injected into an artery (intra-arterial).
    [Show full text]
  • (CHMP) Agenda for the Meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes
    17 May 2021 EMA/CHMP/276743/2021 Human Medicines Division Committee for medicinal products for human use (CHMP) Agenda for the meeting on 17-20 May 2021 Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes 17 May 2021, 09:00 – 19:30, virtual meeting/ room 1C 18 May 2021, 08:30 – 19:30, virtual meeting/ room 1C 19 May 2021, 08:30 – 19:30, virtual meeting/ room 1C 20 May 2021, 08:30 – 19:30, virtual meeting/ room 1C Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021.
    [Show full text]
  • Sotorasib Data at Esmo Virtual Congress 2020
    SOTORASIB DATA AT ESMO VIRTUAL CONGRESS 2020 SEPTEMBER 20, 2020 SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company, including BeiGene, Ltd. or any collaboration or potential collaboration in pursuit of therapeutic antibodies against COVID-19 (including statements regarding such collaboration’s, or our own, ability to discover and develop fully-human neutralizing antibodies targeting SARS-CoV-2 or antibodies against targets other than the SARS-CoV-2 receptor binding domain, and/or to produce any such antibodies to potentially prevent or treat COVID-19), or the Otezla® (apremilast) acquisition (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, outcomes, progress, or effects relating to studies of Otezla as a potential treatment for COVID-19, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K.
    [Show full text]
  • Full Prescribing Information [FDA]
    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------------ADVERSE REACTIONS ----------------------------­ These highlights do not include all the information needed to use The most common adverse reactions (≥ 20%) were diarrhea, musculoskeletal LUMAKRAS safely and effectively. See full prescribing information for pain, nausea, fatigue, hepatotoxicity, and cough. The most common laboratory LUMAKRAS. abnormalities ≥ 25% were decreased lymphocytes, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, LUMAKRAS™ (sotorasib) tablets, for oral use decreased calcium, increased alkaline phosphatase, increased urine protein, Initial U.S. Approval: 2021 and decreased sodium. (6.1) ----------------------------INDICATIONS AND USAGE--------------------------­ To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at LUMAKRAS is an inhibitor of the RAS GTPase family indicated for the 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or treatment of adult patients with KRAS G12C-mutated locally advanced or www.fda.gov/medwatch. metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. (1) ------------------------------DRUG INTERACTIONS -----------------------------­ This indication is approved under accelerated approval based on overall • Acid-Reducing Agents: Avoid coadministration with proton pump response rate (ORR) and duration of response (DOR). Continued approval for inhibitors (PPIs) and H2 receptor antagonists. If an acid-reducing agent this indication may be contingent upon verification and description of clinical cannot be avoided, administer LUMAKRAS 4 hours before or 10 hours benefit in a confirmatory trial(s). (1) after a local antacid. (2.4, 7.1) • Strong CYP3A4 Inducers: Avoid coadministration with strong CYP3A4 ----------------------DOSAGE AND ADMINISTRATION----------------------­ inducers. (7.1) • Recommended dosage: 960 mg orally once daily.
    [Show full text]
  • Update on Molecular Pathology and Role of Liquid Biopsy in Nonsmall Cell Lung Cancer
    EUROPEAN RESPIRATORY REVIEW SERIES ARTICLE P. ABDAYEM AND D. PLANCHARD Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer Pamela Abdayem and David Planchard Number 6 in the Series “Thoracic oncology” Edited by Rudolf Huber and Peter Dorfmüller Dept of Cancer Medicine, Thoracic Group, Gustave Roussy Cancer Campus, Villejuif, France. Corresponding author: David Planchard ([email protected]) Shareable abstract (@ERSpublications) Screening for driver alterations in patients with advanced lung adenocarcinoma and those with squamous cell carcinoma and no/little smoking history is mandatory. Liquid biopsy is evolving constantly and will definitely improve outcomes in thoracic oncology. https://bit.ly/2XjuQrD Cite this article as: Abdayem P, Planchard D. Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. Eur Respir Rev 2021; 30: 200294 [DOI: 10.1183/16000617.0294-2020]. Abstract Copyright ©The authors 2021 Personalised medicine, an essential component of modern thoracic oncology, has been evolving continuously ever since the discovery of the epidermal growth factor receptor and its tyrosine kinase This version is distributed under the terms of the Creative inhibitors. Today, screening for driver alterations in patients with advanced lung adenocarcinoma as well as Commons Attribution those with squamous cell carcinoma and no/little history of smoking is mandatory. Multiplex molecular Non-Commercial Licence 4.0. platforms are preferred to sequential molecular testing since they are less time- and tissue-consuming. In For commercial reproduction this review, we present the latest updates on the nine most common actionable driver alterations in rights and permissions contact nonsmall cell lung cancer.
    [Show full text]
  • Oncology Orals Solid Tumors
    Pharmacy # 2915 Oncology Oral Medications Solid Tumors Enrollment Form Fax Referral To: 1-877-232-5455 Phone: 1-800-896-1464 Address: 500 Ala Moana Blvd., Ste 1-A Honolulu, HI 96813 Six Simple Steps to Submitting a Referral 1 PATIENT INFORMATION (Complete or include demographic sheet) Patient Name: _______________________________________ Address: ____________________________ City, State, ZIP Code: ___________________________________ Preferred Contact Methods: Phone (primary # provided below) Text (cell # provided below) Email (email provided below) Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone. Primary Phone: ____________________________ Alternate Phone: ________________________________ Primary Language: _________________________________ DOB: __________________ Gender: Male Female Email: __________________________________ Last Four of SSN: ________ 2 PRESCRIBER INFORMATION Prescriber’s Name: _________________________________________________________________ State License #: _____________________________________ NPI #: _____________________ DEA #: _____________________ Group or Hospital: _______________________________________________________________ Address: ______________________________________________ City, State, ZIP Code: ______________________________________________________________ Phone: ______________________ Fax: ______________________ Contact Person: ________________________ Contact’s Phone: _______________________ 3 INSURANCE INFORMATION Please fax
    [Show full text]